Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma

References

• Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004;79:867–874.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–1128.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Callander NS, Alsina M, et al. Multiple myeloma, version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15:230–269.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26:149–157.
   PubMed Web of Science ®Google Scholar
• Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e346.
   PubMed Web of Science ®Google Scholar
• Laubach J, Garderet L, Mahindra A, et al. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia [Internet]. 2016;30:1005–1017.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood. 2011;118:3205–3211.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Mateos M-V, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125:2068–2074.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A. Myeloma: management of the newly diagnosed high-risk patient. Hematology. 2016;2016:485–494.
   PubMedGoogle Scholar
• Engelhardt M, Dold SM, Ihorst G, et al. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica. 2016;101:1110–1119.
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Domm A-S, Dold SM, et al. A concise revised myeloma comorbidity index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017;102:910–921.
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Ihorst G, Caers J, et al. Autotransplants in older multiple myeloma patients: hype or hope in the era of novel agents? Haematologica. 2016;101:1276–1278.
   PubMed Web of Science ®Google Scholar
• Rajkumar V. Myeloma today: disease definitions and treatment advances. Am J Hematol. 2016;91:965–965.
   PubMed Web of Science ®Google Scholar
• Giralt S, Garderet L, Durie B, et al. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transpl. 2015;21:2039–2051.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. 2012;87:78–88.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Falco P, et al. Time to first disease progression, but not β2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. Cancer. 2007;110:824–829.
   PubMed Web of Science ®Google Scholar
• Moreau P, San Miguel J, Ludwig H, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi133–vi137.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20:4420–4427.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–2617.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127:165–172.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–2498.
   PubMed Web of Science ®Google Scholar
• Podar. Efficacy of subcutaneous bortezomib in the management of patients with multiple myeloma or relapsed mantle cell lymphoma. Clin Med Insights Ther. 2014;6:15–23.
   Google Scholar
• Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431–440.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol. 2013;31:448–455.
   PubMed Web of Science ®Google Scholar
• Davies FE, Wu P, Jenner M, et al. The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica. 2007;92:1149–1150.
   PubMed Web of Science ®Google Scholar
• Reece DE, Rodriguez GP, Chen C, et al. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol. 2008;26:4777–4783.
   PubMed Web of Science ®Google Scholar
• Reece DE, Trieu Y, Masih-Khan E, et al. Cyclophosphamide and bortezomib with prednisone or dexamethasone for the treatment of relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2016;16:387–394.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Beksac M, Benboubker L, et al. Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. Haematologica. 2013;98:1264–1272.
   PubMed Web of Science ®Google Scholar
• De Waal EGM, De Munck L, Hoogendoorn M, et al. Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients. Br J Haematol. 2015;171:720–725.
   PubMed Web of Science ®Google Scholar
• Garderet L, Iacobelli S, Moreau P, et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomi. J Clin Oncol. 2012;30:2475–2482.
   PubMed Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621–1634.
   PubMed Web of Science ®Google Scholar
• San-Miguel JF, Hungria VTM, Yoon -S-S, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15:1195–1206.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood. 2005;105:3058–3065.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892–3901.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P, et al. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer. 2016;122:2050–2056.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Siegel DS, Lonial S, et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 2013;14:1129–1140.
   PubMed Web of Science ®Google Scholar
• Berenson JR, Yellin O, Bessudo A, et al. Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol. 2013;160:321–330.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Benson DM, Bensinger W, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2012;30:1960–1965.
   PubMed Web of Science ®Google Scholar
• Jakubowiak A, Offidani M, Pégourie B, et al. Randomized phase 2 study of elotuzumab plus bortezomib/dexamethasone (Bd) versus Bd for relapsed/refractory multiple myeloma. Blood. 2016;127:2833–2840.
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. New Engl J Med. 2015;373:1207–1219.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Xie W, Jagannath S, et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014;123:1461–1469.
   PubMed Web of Science ®Google Scholar
• Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110:3281–3290.
   PubMed Web of Science ®Google Scholar
• Parlati F, Lee SJ, Aujay M, et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood. 2009;114:3439–3447.
   PubMed Web of Science ®Google Scholar
• Hájek R, Masszi T, Petrucci MT, et al. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2017;31:107–114.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142–152.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Fonseca R, Siegel D, et al. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016;128:1174–1180.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Stewart AK, Masszi T, et al. Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer J. 2017;7:e554.
   PubMed Web of Science ®Google Scholar
• Moreau P, Joshua D, Chng W-J, et al. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia. 2017;31:115–122.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Stewart AK, Masszi T, et al. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol. 2017;177:404–413.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27–38.
   PubMed Web of Science ®Google Scholar
• Chng W-J, Goldschmidt H, Dimopoulos MA, et al. Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia. 2017;31:1368–1374.
   PubMed Web of Science ®Google Scholar
• Facon T, Lee JH, Moreau P, et al. Overall survival of patients with relapsed or refractory multiple myeloma treated with carfilzomib and dexamethasone versus bortezomib and dexamethasone in the randomized phase 3 ENDEAVOR trial. Int Myeloma Work. 2017;e37-38, OP-044.
   Google Scholar
• Jakubowiak AJ, DeCara JM, Mezzi K. Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies. Hematology. 2017;1–7.
   PubMedGoogle Scholar
• Berenson JR, Cartmell A, Bessudo A, et al. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood. 2016;127:3360–3368.
   PubMed Web of Science ®Google Scholar
• Shah JJ, Stadtmauer EA, Abonour R, et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015;126:2284–2290.
   PubMed Web of Science ®Google Scholar
• Jakubowiak A, Jasielec J, Rosenbaum CA, et al. Final results of phase 1 MMRC trial of selinexor, carfilzomib, and dexamethasone in relapsed/refractory multiple myeloma (RRMM). Blood. 2016;128:973.
   Web of Science ®Google Scholar
• Kupperman E, Lee EC, Cao Y, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010;70:1970–1980.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Tian Z, Zhou B, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011;17:5311–5321.
   PubMed Web of Science ®Google Scholar
• Garcia-Gomez A, Quwaider D, Canavese M, et al. Preclinical activity of the oral proteasome inhibitor MLN9708 in myeloma bone disease. Clin Cancer Res. 2014;20:1542–1554.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Baz R, Wang M, et al. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 2014;124:1038–1046.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Bensinger WI, Zimmerman TM, et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood. 2014;124:1047–1055.
   PubMed Web of Science ®Google Scholar
• Kumar SK, LaPlant B, Roy V, et al. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J. 2015;4:e338.
   Web of Science ®Google Scholar
• Kumar SK, LaPlant BR, Reeder CB, et al. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood. 2016;128:2415–2422.
   PubMed Web of Science ®Google Scholar
• Krishnan A, Kapoor P, Palmer J, et al. A phase I/II trial of ixazomib (Ix), pomalidomide (POM), and dexamethasone (DEX), in relapsed/refractory (R/R) multiple myeloma (MM) patients: responses in double/triple refractory myeloma and poor risk cytogenetics. Blood. 2016;128:3316.
   Web of Science ®Google Scholar
• Voorhees PM, Mulkey F, Hassoun H, et al. Alliance A061202. a phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor based therapy: phase I results. Blood. 2015;126:375.
   Google Scholar
• Kumar S, Grzasko N, Delimpasi S, et al. Phase 2 study of the all-oral combination of ixazomib plus cyclophosphamide and low-dose dexamethasone (ICd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM). Blood. 2016;128:3327.
   Google Scholar
• Chauhan D, Catley L, Li G, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 2005;8:407–419.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Singh A, Brahmandam M, et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2007;111:1654–1664.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Zimmerman TM, Hofmeister CC, et al. Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. Blood. 2016;127:2693–2700.
   PubMed Web of Science ®Google Scholar
• Spencer A, Harrison S, Laubach JP, et al. Pmd-107: marizomib, pomalidomide and low dose-dexamethasone combination study in relapsed/refractory multiple myeloma (NCT02103335): full enrollment results from a phase-1 multicenter, open label study. Blood. 2016; Abstract 3.
   Google Scholar
• Badros A, Singh Z, Dhakal B, et al. Marizomib for central nervous system-multiple myeloma. Br J Haematol. 2017;177:221–225.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Singh AV, Aujay M, et al. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood. 2010;116:4906–4915.
   PubMed Web of Science ®Google Scholar
• Hurchla MA, Garcia-Gomez A, Hornick MC, et al. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia. 2013;27:430–440.
   PubMed Web of Science ®Google Scholar
• Sanchez E, Li M, Wang CS, et al. Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex). Leuk Res. 2017;57:45–54.
   PubMedGoogle Scholar
• Vij R, Savona M, Siegel DS, et al. Clinical profile of single-agent oprozomib in patients with multiple myeloma (MM): updated results from a multicenter, open-label, dose escalation phase 1b/2 study. Blood. 2014;124:34.
   Web of Science ®Google Scholar
• Ghobrial IM, Savona MR, Vij R, et al.Final results from a multicenter, open-label, dose-escalation phase 1b/2 study of single-agent oprozomib in patients with hematologic malignancies. Blood. 2016; Abstr 2110.
   PubMed Web of Science ®Google Scholar
• D’Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082–4085.
   PubMed Web of Science ®Google Scholar
• Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994;87:503–508.
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565–1571.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001;98:492–494.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Celsing F, Turesson I, et al. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol. 2000;109:89–96.
   PubMed Web of Science ®Google Scholar
• Kropff M, Baylon HG, Hillengass J, et al. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica. 2012;97:784–791.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol. 2001;12:991–995.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Giaccone L, Bertola A, et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica. 2001;86:399–403.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Hamilos G, Zomas A, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J. 2004;5:112–117.
   PubMedGoogle Scholar
• García-Sanz R, González-Porras JR, Hernández JM, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia. 2004;18:856–863.
   PubMed Web of Science ®Google Scholar
• Kropff MH, Lang N, Bisping G, et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol. 2003;122:607–616.
   PubMed Web of Science ®Google Scholar
• Hussein MA, Baz R, Srkalovic G, et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc. 2006;81:889–895.
   PubMed Web of Science ®Google Scholar
• Offidani M, Corvatta L, Marconi M, et al. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. Haematologica. 2006;91:133–136.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414–423.
   PubMed Web of Science ®Google Scholar
• Chamberlain PP, Lopez-Girona A, Miller K, et al. Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol. 2014;21:803–809.
   PubMed Web of Science ®Google Scholar
• Havens CG, Bjorklund C, Kang J, et al. IMiDs® immunomodulatory agents regulate interferon-stimulated genes through cereblon-mediated aiolos destruction in multiple myeloma (MM) cells: identification of a novel mechanism of action and pathway for resistance. Blood. 2014;124:3432.
   Web of Science ®Google Scholar
• Quintana FJ, Jin H, Burns EJ, et al. Aiolos promotes TH17 differentiation by directly silencing Il2 expression. Nat Immunol. 2012;13:770–777.
   PubMed Web of Science ®Google Scholar
• Bjorklund CC, Lu L, Kang J, et al. Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Blood Cancer J. 2015;5:e354.
   PubMed Web of Science ®Google Scholar
• Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26:2326–2335.
   PubMed Web of Science ®Google Scholar
• Zhu YX, Braggio E, Shi C-X, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011;118:4771–4779.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063–3067.
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med [Internet]. 2007;357:2133–2142.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123–2132.
   PubMed Web of Science ®Google Scholar
• Wang M, Dimopoulos MA, Chen C, et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood. 2008;112:4445–4451.
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA, Weber DM, Niesvizky R, et al. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol. 2009;82:426–432.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11:29–37.
   PubMed Web of Science ®Google Scholar
• Nijhof IS, Franssen LE, Levin M-D, et al. Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. Blood. 2016;128:2297–2306.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123:1826–1832.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Siegel D, Baz R, et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013;121:1961–1967.
   PubMed Web of Science ®Google Scholar
• San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055–1066.
   PubMed Web of Science ®Google Scholar
• Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02. Blood. 2013;121:1968–1975.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Palumbo A, Corradini P, et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016;128:497–503.
   PubMed Web of Science ®Google Scholar
• Miguel JS, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055–1066.
   PubMed Web of Science ®Google Scholar
• Siegel DS, Weisel KC, Dimopoulos MA, et al. Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. Leuk Lymphoma. 2016;57:2833–2838.
   PubMed Web of Science ®Google Scholar
• Baz RC, Martin TG, Lin H-Y, et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016;127:2561–2568.
   PubMed Web of Science ®Google Scholar
• Larocca A, Montefusco V, Bringhen S, et al. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood. 2013;122:2799–2806.
   PubMed Web of Science ®Google Scholar
• Baz RC, Martin TG, Lin H-Y, et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016;127:2561–2568.
   PubMed Web of Science ®Google Scholar
• Badros AZ, Hyjek E, Ma N, et al. Pembrolizumab in combination with pomalidomide and dexamethasone for relapsed/refractory multiple myeloma (RRMM). Blood. 2016;128:490.
   Web of Science ®Google Scholar
• Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and -tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006;108:3441–3449.
   PubMed Web of Science ®Google Scholar
• San-Miguel JF, Richardson PG, Günther A, et al. Phase ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2013;31:3696–3703.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Schlossman RL, Alsina M, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013;122:2331–2337.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Hungria VTM, Yoon -S-S, et al. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016;127:713–721.
   PubMed Web of Science ®Google Scholar
• San-Miguel JF, Hungria VTM, Yoon -S-S, et al. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematol. 2016;3:e506–e515.
   PubMed Web of Science ®Google Scholar
• Santo L, Hideshima T, Kung AL, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 2012;119:2579–2589.
   PubMed Web of Science ®Google Scholar
• Mishima Y, Santo L, Eda H, et al. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death. Br J Haematol. 2015;169:423–434.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Qi J, Paranal RM, et al. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proc Natl Acad Sci U S A. 2016;113:13162–13167.
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Richardson PG, Yee AJ, et al. Selective HDAC6 inhibitor ACY-241, an oral tablet, combined with pomalidomide and dexamethasone: safety and efficacy of escalation and expansion cohorts in patients with relapsed or relapsed-and-refractory multiple myeloma (ACE-MM-200 Study). Blood. 2016;128:3307.
   Web of Science ®Google Scholar
• Vogl DT, Raje N, Jagannath S, et al. Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. Clin Cancer Res. 2017 Jan 4. doi:10.1158/1078-0432.CCR-16-2526. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• McCudden C, Axel AE, Slaets D, et al. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. Clin Chem Lab Med. 2016;54:1095–1104.
   PubMed Web of Science ®Google Scholar
• Lin P, Owens R, Tricot G, et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121:482–488.
   PubMed Web of Science ®Google Scholar
• Domingo-Domènech E, Domingo-Clarós A, Gonzàlez-Barca E, et al. CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients. Haematologica. 2002;87:1021–1027.
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Bell AJ, Cusack R, et al. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood. 1991;77:1071–1079.
   PubMed Web of Science ®Google Scholar
• Green DJ, Orgun NN, Jones JC, et al. A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. Cancer Res. 2014;74:1179–1189.
   PubMed Web of Science ®Google Scholar
• Teiluf K, Seidl C, Blechert B, et al. α-Radioimmunotherapy with 213Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma. Oncotarget. 2015;6:4692–4703.
   PubMed Web of Science ®Google Scholar
• Podar K, Jäger D. Targeting the immune niche within the bone marrow microenvironment: the rise of immunotherapy in multiple myeloma. Curr Cancer Drug Targets. 2017;17:1–1.
   Google Scholar
• Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387:1551–1560.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754–766.
   PubMed Web of Science ®Google Scholar
• Mateos M-V, Estell J, Barreto W, et al. Efficacy of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory myeloma based on prior lines of therapy: updated analysis of Castor. Blood. 2016;128:1150.
   Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319–1331.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Dimopoulos MA, Belch A, et al. Efficacy of daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients with 1 to 3 prior lines of therapy: updated analysis of Pollux. Blood. 2016;128:1151.
   Google Scholar
• Moreau P, Kaufman JL, Sutherland HJ, et al. Efficacy of daratumumab, lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone for relapsed or refractory multiple myeloma among patients with 1 to 3 prior lines of therapy based on previous treatment exposure: updated analysis. Blood. 2016;128:489.
   Google Scholar
• Avet-Loiseau H, Casneuf T, Chiu C, et al. Evaluation of minimal residual disease (MRD) in relapsed/refractory multiple myeloma (RRMM) patients treated with daratumumab in combination with lenalidomide plus dexamethasone or bortezomib plus dexamethasone. Blood. 2016;128:246.
   Web of Science ®Google Scholar
• Nooka AK, Joseph N, Boise LH, et al. Clinical efficacy of daratumumab, pomalidomide and dexamethasone in relapsed, refractory myeloma patients: utility of retreatment with daratumumab among refractory patients. Blood. 2016;128:492.
   Web of Science ®Google Scholar
• Usmani SZ, Nahi H, Mateos M-V, et al. Open-label, multicenter, dose escalation phase 1b study to assess the subcutaneous delivery of daratumumab in patients (pts) with relapsed or refractory multiple myeloma (PAVO). Blood. 2016;128:1149.
   Web of Science ®Google Scholar
• Deckert J, Wetzel M-C, Bartle LM, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res. 2014;20:4574–4583.
   PubMed Web of Science ®Google Scholar
• Jiang H, Acharya C, An G, et al. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2016;30:399–408.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Mikhael J, Usmani SZ, et al. Preliminary results from a phase Ib study of isatuximab in combination with pomalidomide and dexamethasone in relapsed and refractory multiple myeloma. Blood. 2016;128:2123.
   Web of Science ®Google Scholar
• Martin TG, Mannis GN, Chari A, et al. Phase Ib study of isatuximab and carfilzomib in relapse and refractory multiple myeloma. Blood. 2016;128:2111.
   Google Scholar
• Raab MS, Chatterjee M, Goldschmidt H, et al. A phase I/IIa study of the CD38 antibody MOR202 alone and in combination with pomalidomide or lenalidomide in patients with relapsed or refractory multiple myeloma. Blood. 2016;128:1152.
   Google Scholar
• Tai Y-T, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112:1329–1337.
   PubMed Web of Science ®Google Scholar
• van Rhee F, Szmania SM, Dillon M, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009;8:2616–2624.
   PubMed Web of Science ®Google Scholar
• Guo H, Cruz-Munoz M-E, Wu N, et al. Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring Src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells. Mol Cell Biol. 2015;35:41–51.
   PubMed Web of Science ®Google Scholar
• Collins SM, Bakan CE, Swartzel GD, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013;62:1841–1849.
   PubMed Web of Science ®Google Scholar
• Zonder JA, Mohrbacher AF, Singhal S, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012;120:552–559.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Jagannath S, Moreau P, et al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study. Lancet Haematol. 2015;2:e516–e527.
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621–631.
   PubMed Web of Science ®Google Scholar
• Mateos M-V, Granell M, Oriol A, et al. Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma. Br J Haematol. 2016;175:448–456.
   PubMed Web of Science ®Google Scholar
• Touzeau C, Dousset C, Le Gouill S, et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014;28:210–212.
   PubMed Web of Science ®Google Scholar
• Touzeau C, Ryan J, Guerriero J, et al. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia. 2016;30:761–764.
   PubMed Web of Science ®Google Scholar
• Kumar S, Vij R, Kaufman JL, et al. Venetoclax monotherapy for relapsed/refractory multiple myeloma: safety and efficacy results from a phase I study. Blood. 2016;128:488.
   Google Scholar
• Touzeau C, Le Gouill S, Mahé B, et al. Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14). Haematologica. 2017;102:e112–e114.
   PubMed Web of Science ®Google Scholar
• Moreau P, Chanan-Khan AA, Roberts AW, et al. Venetoclax combined with bortezomib and dexamethasone for patients with relapsed/refractory multiple myeloma. Blood. 2016;128:975.
   Web of Science ®Google Scholar
• Tai Y-T, Landesman Y, Acharya C, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014;28:155–165.
   PubMed Web of Science ®Google Scholar
• Vogl DT, Dingli D, Cornell RF, et al. Selinexor and low dose dexamethasone (Sd) in patients with lenalidomide, pomalidomide, bortezomib, carfilzomib and anti-CD38 Ab refractory multiple myeloma (MM): STORM study. Blood. 2016;128:491.
   Web of Science ®Google Scholar
• Bahlis NJ, Kotb R, Sebag M, et al. Selinexor in combination with bortezomib and dexamethasone (SdB) demonstrates significant activity in patients with refractory multiple myeloma (MM) including proteasome-inhibitor refractory patients: results of the phase I Stomp trial. Blood. 2016;128:977.
   Web of Science ®Google Scholar
• Chen C, Kotb R, Sebag M, et al. Selinexor shows synergy in combination with pomalidomide and low dose dexamethasone in patients with relapsed /refractory multiple myeloma. Blood. 2016;128:3330.
   Google Scholar
• Argueta C, Chang H, Kashyap T, et al. Synergistic anti-tumor effect of KPT-8602, a second generation selective inhibitor of nuclear export (SINE) compound, and panobinostat, a pan-histone deacetylase (HDAC) inhibitor in multiple myeloma. Blood. 2016;128:3298.
   Web of Science ®Google Scholar
• Kraus M, Bader J, Overkleeft H, et al. Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance. Blood Cancer J. 2013;3:e103.
   PubMed Web of Science ®Google Scholar
• Driessen C, Kraus M, Joerger M, et al. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica. 2016;101:346–355.
   PubMed Web of Science ®Google Scholar
• Driessen C, Müller R, Novak U, et al. The HIV protease inhibitor nelfinavir in combination with bortezomib and dexamethasone (NVd) has excellent activity in patients with advanced, proteasome inhibitor-refractory multiple myeloma: a multicenter phase II trial (SAKK 39/13). Blood. 2016;128:487.
   Web of Science ®Google Scholar
• Sanchez E, Li M, Kitto A, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012;158:727–738.
   PubMed Web of Science ®Google Scholar
• Huang H-W, Chen C-H, Lin C-H, et al. B-cell maturation antigen is modified by a single N-glycan chain that modulates ligand binding and surface retention. Pro Natl Acad Sci U S A. 2013;110:10928–10933.
   PubMed Web of Science ®Google Scholar
• Ryan MC, Hering M, Peckham D, et al. Antibody targeting of B-cell maturation antigen on malignant plasma cells. Mol Cancer There. 2007;6:3009–3018.
   PubMed Web of Science ®Google Scholar
• Tai Y-T, Mayes PA, Acharya C, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123:3128–3138.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Popat R, Trudel S, et al. First in human study with GSK2857916, an antibody drug conjugated to microtubule-disrupting agent directed against B-cell maturation antigen (BCMA) in patients with relapsed/refractory multiple myeloma (MM): results from study BMA117159 part 1 dose escalation study. Blood. 2016;128:1148.
   Web of Science ®Google Scholar
• Seckinger A, Delgado JA, Moser S, et al. Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell. 2017;31:396–410.
   PubMed Web of Science ®Google Scholar
• Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19:2048–2060.
   PubMed Web of Science ®Google Scholar
• Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2014;385:517–528.
   PubMed Web of Science ®Google Scholar
• Maus MV, Grupp SA, Porter DL, et al. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. 2014;123:2625–2635.
   PubMed Web of Science ®Google Scholar
• Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity. 2013;39:49–60.
   PubMed Web of Science ®Google Scholar
• Garfall AL, Maus MV, Hwang W-T, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med. 2015;373:1040–1047.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Garfall AL, Stadtmauer EA, et al. B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) for multiple myeloma (MM): initial safety and efficacy from a phase I study. Blood. 2016;128:1147.
   Google Scholar
• Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–1034.
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
   PubMed Web of Science ®Google Scholar
• Görgün G, Samur MK, Cowens KB, et al. Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin Cancer Res. 2015;21:4607–4618.
   PubMed Web of Science ®Google Scholar
• San Miguel J, Mateos M-V, Shah JJ, et al. Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): keynote-023. 2015;126(23). Abstr 505.
   Google Scholar
• Straathof KC, Pulè MA, Yotnda P, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005;105:4247–4254.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Tian Z, Nicholson B, et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012;22:345–358.
   PubMed Web of Science ®Google Scholar
• Tian Z, D’Arcy P, Wang X, et al. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood. 2014;123:706–716.
   PubMed Web of Science ®Google Scholar
• Song Y, Ray A, Li S, et al. Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma. Leukemia. 2016;30:1877–1886.
   PubMed Web of Science ®Google Scholar
• Matyskiela ME, Zhang W, Man H-W, et al. A cereblon modulator (CC-220) with improved degradation of ikaros and aiolos. J Med Chem. 2017;6b01921.
   Google Scholar
• Bjorklund CC, Kang J, Lu L, et al. CC-220 Is a potent cereblon modulating agent that displays anti-proliferative, pro-apoptotic and immunomodulatory activity on sensitive and resistant multiple myeloma cell lines. Blood. 2016;128:1591.
   Web of Science ®Google Scholar
• Winter GE, Buckley DL, Paulk J, et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Sci (80-.). 2015;348:1376–1381.
   PubMed Web of Science ®Google Scholar
• Andrulis M, Lehners N, Capper D, et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 2013;3:862–869.
   PubMed Web of Science ®Google Scholar